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A docetaxel (DX) lipid conjugate 2’-(2-bromohexadecanoyl)-docetaxel (2-Br-C16-DX) is
synthesized to enhance the drug loading, entrapment and retention in liquid oil-filled lipid
nanoparticles (NPs). The conjugate is successfully entrapped in the previously optimized NPs with
an entrapment efficiency of 56.8%. In-vitro release studies in 100% mouse plasma show an initial
45% burst release with no additional release within 8 hr. The conjugate is able to be hydrolyzed to
release DX by esterases in-vitro. The conjugate is less potent than unmodified DX in DU-145 and
4T1 cells. However, NPs containing the conjugate show significantly higher cytotoxicity
compared to its free form especially in 4T1 cells. In-vivo, the AUC0-∞ value of NP-formulated 2-
Br-C16-DX is about 100-fold higher than DX formulated in Taxotere. Furthermore, 2-Br-C16-DX
NPs improve DX AUC 4.3-fold compared to Taxotere. The high concentration and prolonged
exposure of both 2-Br-C16-DX and DX from 2-Br-C16-DX NPs in circulation result in a 10-fold
and 1.5-fold higher accumulation of 2-Br-C16-DX and DX, respectively, in tumors compared to
Taxotere. In mice bearing syngeneic 4T1 tumors, 2-Br-C16-DX NPs show markedly greater
anticancer efficacy as well as survival benefit over all controls. The results of these studies support
that the oil-filled NPs containing hydrolyzable lipophilic DX prodrug 2-Br-C16-DX improve the
therapeutic index of DX and are more efficacious in the treatment of breast cancer.
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1. Introduction
Docetaxel (DX) is a potent anticancer drug used to treat various cancers in clinic.[1–3]
Previously, liquid-oil filled NPs were developed to deliver DX. However, despite the
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desirable formulation properties (e.g., monodisperse particle size, apparent drug entrapment
efficiency, etc.), DX was found to be very quickly released in mouse plasma in-vitro. To
overcome the poor retention of DX in the oil-filled NPs in simple aqueous phase and in
biologically relevant medium, DX was modified by attaching fatty acid chains with different
chain lengths to the 2’-position of DX via an ester bond.[4] The three DX-lipid conjugates
synthesized in the previous studies increased the drug solubility in oil phase by 10-fold.
Consequently, the DX-lipid conjugates were well retained in the NPs even in 100% plasma.
The retention of DX conjugates in the long-circulating NPs resulted in significantly reduced
elimination and high and prolonged systemic drug exposure.
However, in-vitro cytotoxicity studies revealed that these DX conjugates were much less
potent than the unmodified DX.[4] Similar results have been reported by other groups.[5] It
has been long recognized that the 2’-OH is critical for the microtubule binding and cytotoxic
effect of DX.[6] Hence, the biological activity of these ester prodrugs mostly depends on the
liberation of active DX. The compromised cytotoxicity suggests inefficient release of DX in
cell culture. The in-vitro hydrolysis and in-vivo pharmacokinetics also revealed sub-optimal
hydrolysis kinetics of these conjugates.[4]
Ali et al. synthesized a series of lipid paclitaxel (PX) prodrugs with or without a bromine
atom at the 2-position on the fatty acid chain.[7] In general, the prodrugs lacking bromine
were 50- to 250-fold less active than their bromoacyl counterparts indicating that the
electron-withdrawing group facilitated the cleavage of active PX. The bromoacylated PX
showed higher anticancer efficacy against OVCAR-3 tumor in-vivo.[7,8] Their findings
suggest that this rationale and facile modification has the potential to favorably change the
physicochemical and biological properties of the DX conjugates.
The objective of these present studies was to further tune the prodrug hydrolysis kinetics
while retaining the high drug entrapment and retention in the oil-filled NPs. With optimized
activation kinetics, the new prodrug containing NPs were expected to achieve sustained
release of active drug, low systemic toxicity, and enhanced antitumor efficacy in-vivo.
2. Results
2.1. Synthesis and characterization of 2-Br-C16-DX
DX was modified to the more lipophilic prodrug, 2-Br-C16-DX, by a one-step esterification
reaction with a 2-bromohexadecanoyl chain attached to the 2’-position of DX (Figure 1).
The 2’-OH is the most reactive hydroxyl group among the multiple hydroxyl groups in DX
molecule, followed by 7-OH and 10-OH.[5] The presence of bromine on the acyl chain made
the carboxylic acid more reactive than its counterpart lack of bromine so that in addition to
2’-substitution, byproducts with 7- and 10-substitution were also formed. Pure 2’-
monosubstituted DX conjugate was obtained after purification by preparative TLC and
confirmed by TLC, NMR and mass spectrometry.
2.2. 2-Br-C16-DX digestion
In fresh mouse plasma, 45% of 2-Br-C16-DX was hydrolyzed to DX in 48 hr and 35% of 2-
Br-C16-DX remained intact in 48 hr (Figure 2). The mass balance did not reach 100% after
48 hr incubation suggesting the presence of alternative degradation and/or metabolic
pathways.
2.3. Preparation and characterization of 2-Br-C16-DX BTM NPs
The oil-filled NPs were able to entrap 2-Br-C16-DX with an entrapment efficiency of 56.8 ±
2.8% as measured by SEC. The 2-Br-C16-DX NPs had a mean particle size of 210 ± 2.15
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nm with a zeta potential of −5.52 ± 0.97 mV. The 2-Br-C16-DX NPs were physically and
chemically stable at 4°C upon long-term storage. The particle size slightly increased from
210 nm to 230 nm and 2-Br-C16-DX concentration in the NP suspension was unchanged for
at least 5 months.
2.4. In-vitro drug release in mouse plasma
The release of 2-Br-C16-DX from NPs in 100% mouse plasma was studied using the “ex-
vivo” method developed in previous studies.[4] Similar to our previous findings, an initial
45% burst release was observed upon spiking into the mouse plasma with no additional
release within 8 hr (Figure 3).
2.5. In-vitro cytotoxicity
The in-vitro cytotoxicity was evaluated in two cell lines; DU-145 human prostate cancer
cells and 4T1 murine breast cancer cells. In DU-145 cells, free 2-Br-C16-DX was 16.4-fold
less active than DX (Figure 4A). The cytotoxicity of 2-Br-C16-DX NPs increased 6.5-fold
compared to free 2-Br-C16-DX, which was still 2.5-fold lower than DX.
In 4T1 cells, free 2-Br-C16-DX was 2.8-fold less potent than DX (Figure 4B). When
entrapped in NPs, the cytotoxicity increased 12.7-fold compared to free 2-Br-C16-DX. More
impressively, the IC50 value of 2-Br-C16-DX NP was 4.5-fold lower than that of free DX.
The blank NPs did not show significant cytotoxicity in either cell lines (IC50 was 1842 ±
287 nM in DU-145 cells and 2955 ± 435 nM in 4T1 cells with drug equivalent doses,
respectively).
2.6. In-vivo pharmacokinetics of 2-Br-C16-DX NPs
The plasma concentration-time curves in mice receiving i.v. bolus injections of Taxotere or
2-Br-C16-DX NPs at a dose of 10 mg DX/kg are shown in Figure 5A. Pharmacokinetic
parameters obtained using a noncompartmental model of analysis are summarized in Table
1. The AUC0–∞ value of NP-formulated 2-Br-C16-DX was about 100-fold higher than that
of Taxotere. The DX concentration in plasma was below the lower limit of quantification
after 8 hr, whereas 2-Br-C16-DX could be detected until 96 hr. The terminal half-life of NP-
formulated 2-Br-C16-DX was 8.7-fold higher compared to that of Taxotere. The plasma
concentrations of DX hydrolyzed from 2-Br-C16-DX were determined and shown in Figure
5B. DX concentrations of Taxotere are also shown as a reference for comparison. The
pharmacokinetic parameters of DX from 2-Br-C16-DX NP are also shown in Table 1. The
DX from 2-Br-C16-DX NP was detectable until 24 hr and below the lower limit of
quantification after that. 2-Br-C16-DX NP improved DX AUC 4.3-fold compared to
Taxotere. The terminal half-life of DX from 2-Br-C16-DX NP was comparable with that of
Taxotere but its MRT was 6.4-fold higher than that of Taxotere.
The biodistribution of 2-Br-C16-DX and DX in main organs and tumors after i.v.
administration of 2-Br-C16-DX NP and Taxotere is presented in Figure 6. The
concentrations of DX from Taxotere in all organs rapidly decreased over time except for in
tumors (Figure 6B). The lack of time-dependent elimination in the tumor likely reflects the
abnormal tumor vasculature and dysfunctional lymphatic drainage. The overall
concentrations of 2-Br-C16-DX were significantly higher than DX in all organs and tumors.
A significant accumulation of 2-Br-C16-DX in liver and spleen was observed after the
administration of 2-Br-C16-DX NP (Figure 6A). The 2-Br-C16-DX concentration in liver
and spleen increased in the first several hours indicating the slow uptake of NPs by RES.
The tumor accumulation of 2-Br-C16-DX and DX was shown in Figure 7. The AUC0–96 of
2-Br-C16-DX was 10-fold higher compared to Taxotere in 4T1 solid tumors (Table 2). The
DX from 2-Br-C16-DX NPs in the tumor generally increased with time and the AUC0–96
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was 1.5-fold higher than that of Taxotere. The AUCplasma and AUCtumor of Taxotere
obtained in these studies are comparable with other reports in the literature.[9, 10]
2.7. In-vivo antitumor efficacy
The antitumor efficacy of 2-Br-C16-DX NP was evaluated in a 4T1 breast cancer syngeneic
mouse model. In the first study, mice were treated with a low dose of 2-Br-C16-DX NP and
Taxotere with high dose frequency (10 mg DX or conjugate/kg, twice a week). The greatest
tumor growth inhibition was observed with 2-Br-C16-DX NP treatment group (Figure 8).
Taxotere and free 2-Br-C16-DX also showed some antitumor effect as compared to naïve
group. A statistically significant difference of 2-Br-C16-DX NP with all other treatments
was observed at day 13 and 15, with post-hoc least significant difference test.
In the second efficacy study, 2-Br-C16-DX NP was administered at predetermined MTD
and dose frequency was adjusted to Q7d. Tumor volume increased with control, blank NPs,
free 2-Br-C16-DX and Taxotere administration (Figure 9). The most significant tumor
growth inhibition was observed with 2-Br-C16-DX NP treatment group. A statistically
significant difference of 2-Br-C16-DX NP with all other treatments was observed starting
from day 7 and continued to the end of the study, with post-hoc Tukey’s test. Figure 10
shows the Kaplan-Meier survival curves of mice until day 23. The 50% survival time of
control, blank NPs, free 2-Br-C16-DX and Taxotere groups was between 14 days and 19
days. All mice in naive, blank NPs, free 2-Br-C16-DX and Taxotere groups died within 21
days. In 2-Br-C16-DX NP treatment group, 100% survival through day 23 was observed.
3. Discussion
In the present studies, a lipophilic DX conjugate 2-Br-C16-DX was synthesized and
characterized. The new conjugate was well entrapped and retained in the oil-filled NPs. The
digestion kinetics of 2-Br-C16-DX was desirable. The retention of the conjugate in the long-
circulating NPs, along with its very different digestion kinetics, resulted in a significantly
improved pharmacokinetic profile, blood exposure of DX and tumor accumulation, which in
turn led to superior antitumor efficacy.
Previously, three DX-lipid conjugates were synthesized to overcome the poor retention of
DX in the oil-filled NPs.[4] The >10-fold increase in the solubility of DX conjugates in
Miglyol 808 compared to DX allowed for a significant increase in drug loading, entrapment
and retention in plasma. However, as prodrugs, their digestion kinetics was not optimal. To
further optimize the hydrolysis kinetics while retain the good drug entrapment and retention,
the DX conjugate was modified by choosing a medium-chain fatty acid, and with a bromine
at the 2-position of the lipid chain. The new DX conjugate 2-Br-C16-DX was successfully
encapsulated in the oil-filled NPs with good retention in mouse plasma. The ester bond is
more susceptible to hydrolysis with an electron-withdrawing group at the 2-position. 2-Br-
C16-DX was slowly hydrolyzed to DX to an extent of 45% in 48 hr. The sustained
hydrolysis is expected to benefit the slow release of DX in-vivo and further improve the DX
blood exposure.
The cytotoxicity of 2-Br-C16-DX NP was 6.5-fold and 12.7-fold higher compared to free 2-
Br-C16-DX in DU-145 and 4T1 cells, respectively. The higher cytotoxicity of 2-Br-C16-DX
NP may be explained by increased cellular uptake and/or different cellular compartmental
sequester facilitated by NP. These factors may also contribute to the higher cytotoxicity of
2-Br-C16-DX NP in the highly aggressive breast cancer cell 4T1 compared to unmodified
free DX. The low sensitivity of 4T1 cells to DX is probably due to their extremely rapid
proliferation as well as other intrinsic detoxification mechanisms (e.g., degradation of DX).
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Hence, the uptake of high drug payload NPs by endocytosis followed by sustained release of
DX may play essential roles in the improved cytotoxicity of 2-Br-C16-DX NP in 4T1 cells.
In-vivo, NP-formulated 2-Br-C16-DX achieved 100-fold higher AUC compared to
Taxotere. The remarkably high AUC, long terminal half-life and long MRT were attributed
to the stable anchoring of 2-Br-C16-DX in the long-circulating NPs as predicted by the in-
vitro release study. The elimination routes of 2-Br-C16-DX include: 1) uptake of drug
containing NPs by RES, 2) release of conjugate followed by elimination as free drug, and 3)
hydrolysis of the conjugate to DX. Due to sustained hydrolysis, the AUC of DX in the
plasma after the administration of 2-Br-C16-DX NPs was over 4-fold higher than that of
Taxotere when the DX dose was the same. The 2-Br-C16-DX NPs served as a drug reservoir
and released free DX in a sustained manner. The high concentration and prolonged exposure
of both 2-Br-C16-DX and DX from 2-Br-C16-DX NPs in the plasma were beneficial to their
passive tumor accumulation via the EPR effect. The AUCtumor of 2-Br-C16-DX was 10-fold
higher than that of Taxotere. The AUCtumor of DX from 2-Br-C16-DX NP was 1.5-fold
greater than that of Taxotere. However, the overall ratio of AUCtumor of DX from 2-Br-C16-
DX NP to that of total 2-Br-C16-DX was only 14.7% at 96 hr. The DX in the tumor was
from two potential routes: direct uptake of DX from the systemic circulation and cleavage
from the 2-Br-C16-DX accumulated in the tumors. The clear ascending trend of DX with
time in the tumor suggests that the in-situ hydrolysis dominated the DX tumor
concentration. The low ratio of hydrolysis in the tumor in-vivo suggests low esterase activity
in 4T1 tumor. The non-specific esterase activity in various human malignant tumors has
been studied by histochemical analysis. It has been previously reported that the esterase
activity in breast tumors is generally low.[11, 12] In contrast, esterase activity is highly
elevated in some tumor types compared to their normal tissue of origin such as colon and
rectum adenocarcinoma, and thyroid tumors. It is likely that these tumor types with high
esterase activity would serve as better models for the ester prodrugs that mostly count on the
enzymatic conversion to their active forms to exert antitumor effects. The NP-formulated 2-
Br-C16-DX showed a marked accumulation in liver and spleen and the accumulation was
increasing during the first several hours of the study, which clearly indicates a slow uptake
of drug containing NPs by RES. Although PEGylation reduces RES clearance, significant
accumulation in RES-related organs is unfortunately still a typical distribution pattern for
most of the NPs.[13–16]
Murine breast cancer 4T1 is a highly aggressive and metastatic tumor model. 4T1 tumors
spontaneously metastasize to the lung, liver, lymph nodes and brain while the primary tumor
grows in-situ after injected s.c. into BALB/c mice. The tumor growth and metastatic spread
of 4T1 cells in BALB/c mice very closely mimic human breast cancer.[17, 18] The in-vivo
efficacy study in mice bearing breast cancer 4T1 solid tumor using low dose (10 mg DX or
conjugate/kg) demonstrated a statistically significant tumor growth inhibition effect by 2-Br-
C16-DX NP compared to the standard-of-care therapy, which was consistent with their
superior plasma pharmacokinetics and tumor distribution. However, given the high
aggressiveness of 4T1 tumor model, it is not surprising that the low dose regimen did not
achieve optimal antitumor efficacy. Since 2-Br-C16-DX NP was much better tolerated than
Taxotere as indicated by its higher MTD, higher doses can be given expecting to achieve
maximum tumor inhibition. Total NP dose was 455 mg/kg when the conjugate was dosed at
70 mg/kg. In the second efficacy study, the tumor growth was significantly suppressed by
only two doses of 2-Br-C16-DX NP and the suppression effect continued to at least day 23.
The long-lasting antitumor effect of 2-Br-C16-DX NP reflected its prolonged exposure in
the circulation as well as in tumors. In contrast, in Taxotere treatment group, after the last
treatment at day 7, tumor growth quickly resumed. The rapid tumor growth after the
termination of the treatment caused 100% mortality in 21 days despite its antitumor efficacy
during the treatment. The short antitumor effect of Taxotere was consistent with its short
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half-life in-vivo. Moreover, since human plasma esterase activity is much lower than
mouse,[19, 20] it can be anticipated that in human or in esterase-deficient mice, 2-Br-C16-DX
NP will be even better tolerated than in BALB/c mice and higher doses are allowed.
4. Conclusions
The 2-Br-C16-DX NP developed in these studies maintained the high drug entrapment and
long drug retention in the NPs while improving the hydrolysis kinetics of the conjugate in-
vitro. The 2-Br-C16-DX NP developed in these studies had long circulation in the blood,
high accumulation in the tumor and low toxicity, which therefore led to superior antitumor
efficacy and less systemic toxicity in-vivo. Collectively, these studies demonstrate that the
oil-filled lipid NPs containing a DX-lipid conjugate with fine-tuned lipophilicity and
activation kinetics successfully improved the therapeutic index of DX. The encouraging
results of these studies suggest that the novel formulation holds promise for further
preclinical development.
5. Experimental Section
Materials and Animals: DX, PX, 2-bromohexadecanoic acid (>99%), 4-(dimethylamino)
pyridine (DMAP) and N,N’-dicyclohexyl-carboiimide (DCC, 99%) were purchased from
Sigma-Aldrich (St. Louis, MO). Miglyol 808 was obtained from Sasol (Witten, Germany).
Polyoxyl 20-stearyl ether (Brij 78) was obtained from Uniqema (Wilmington, DE). D-alpha-
tocopheryl polyethylene glycol-1000 succinate (Vitamin E TPGS) was purchased from
Eastman Chemicals (Kingsport, TN). BALB/c mouse plasma was purchased from
Innovative Research Inc. (Novi, MI). Sepharose CL-4B was purchased from GE Healthcare
(Uppsala, Sweden). Hybrid-SPE® cartridge was purchased from Sigma-Aldrich Supelco (St.
Louis, MO).
The human prostate cancer cell line DU-145, and murine breast cancer cell line 4T1 were
obtained from American Type Culture Collection (ATCC) and were maintained in
RPMI-1640 medium with 10% fetal bovine serum (FBS). Female BALB/c mice, 4 to 5
weeks old, were purchased from Charles River (Wilmington, MA) and housed in a
pathogen-free room. All experiments involving mice were conducted according to an
approved animal protocol by the University of North Carolina Institutional Animal Care and
Use Committee.
General procedure for the synthesis of 2’-(2-bromohexadecanoyl)-docetaxel (2-Br-C16-
DX)[7]
A flame-dried round-bottom flask was charged with (±)-2-bromohexadecanoic acid (0.62 g,
1.85 × 10−3 mol, 1.5N) and DCC (0.5 g, 2.47 × 10−3 mol, 2N) in dry CH2Cl2 (200 mL)
under argon. The solution was stirred for 10 min at room temperature. DX (1.0 g, 1.24 ×
10−3 mol, 1N) was added along with a catalytic amount of DMAP (0.15 g, 1.24 × 10−3 mol,
1N) and the reaction mixture was stirred at room temperature for an extra 5 min. The
reaction was monitored by TLC (CH2Cl2: MeOH 95:5 v/v; Rf = 0.58) for completion. The
white precipitate of dicyclohexyl urea byproduct was filtered through a fritted funnel, and
the filtrate was evaporated under vaccuo. The crude product was purified by preparative
TLC in CHCl3: MeOH (95:5). The silica gel was removed by filtration through a fine fritted
funnel and the filtrate was evaporated under vaccuo to give the desired product as a white
powder (0.4 mg, 86%). 1H NMR (400 MHz, CDCl3): δ (ppm) = 0.8 (t, 3H, –CH3(CH2)14),
1.05 (s, 6H, –H16,17), 1.16 (s, 9H, –H7’–9’), 1.19 (s, 3H, –H19), 1.23 (m, 28H, –
(CH2)14CH3), 1.68 (s, 3H, –H18), 1.78 (m, 2H, –H14), 1.67 (d, 2H, –CH2C1”), 1.87 (s, 3H, –
H22), 2.24 (m, 1H, –H3), 2.38 (s, 1H, –H7), 3.86 (d, 1H, –H4), 4.12 (d, 1H, –H2), 4.2 (t, 1H,
–CHBrC1”), 4.26 (t, 2H, –H13), 4.88 (d, 1H, –H10), 5.2 (d, 2H, –H20), 5.22 (d, 1H, –H2’),
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5.62 (d, 1H, –H3’), 7.22–7.53 (m, 8H, –Ar-H26–28 and Ar-H30–35), 8.05 (d, 2H, –Ar-
H25,29). 13C NMR (100 MHz, CD3OD): δ (ppm) = 8.9 (–C19), 14.1 (–CH3(CH2)20), 20.9 (–
C18), 22.6 (–C22), 23.7 (–(CH2)19CH2CH3), 27 (–C16,17), 28.1 (–C7’–9’), 29.6 (–
(CH2)14C1”), 31.9 (–C6,14), 43.1 (–C15), 44.5 (–C3), 45 (–CHBr), 46.4 (–C3’), 57.5 (–C8),
71.8 (–C13), 72.1 (–C7), 74.4 (–C2), 75 (–C10), 75.3 (–C20), 78.9 (–C6’), 79.9 (–C1), 80.9 (–
C4), 84.2 (–C5), 126.3 (–C31,33,35), 128.9 (–C32,34), 129.2 (–C26,28), 130.2 (–C24,25,29),
133.6 (–C27), 135.5 (–C11), 138.9 (–C12), 154.2 (–C5’), 167 (–C23), 167.3 (–C21), 169 (–C1),
169.7 (–C1”), 211.5 (–C9).
Characterization of DX and DX conjugates
Electrospray Ionization (ESI) coupled with direct injection was employed to determine the
m/z of the final synthetic conjugate product by Thermo Scientific TSQ Quantum Access
with positive ionization. The m/z of the observed molecular ion was 1125, which clearly
corresponded to the H+ adduct of 2-Br-C16-DX.
The 2-Br-C16-DX concentrations were quantified by HPLC using a Finnigan Surveyor
HPLC system with a Photodiode Array (PDA) detector, autosampler and LC pump plus with
a Inertsil® ODS-3 column (4 µm, 4.6 × 150 mm, GL Sciences) at 25°C. Chromatographic
separation was achieved by gradient elution using mobile phase 2-propanol, acetonitrile
(ACN) and water (5: 55: 40 v/v/v). The flow rate was 1.0 mL/min and the total run time was
25 min for each 25 µL injection. The wavelength was 230 nm. The DX concentration was
quantified by LC/MS/MS as described previously.[4]
2-Br-C16-DX digestion in fresh mouse plasma
The esterase digestion study was performed in fresh BALB/c mouse plasma. The 2-Br-C16-
DX NPs (0.5 mg/mL) were spiked into the plasma to make a final concentration of 10 µg/
mL. The mixture was incubated at 37°C in a water bath shaker. At designated time points,
100 µL of digestion mixture was removed. The concentration of 2-Br-C16-DX was
determined by Hybrid-SPE precipitate method as described previously followed by HPLC
analysis.[4] The % 2-Br-C16-DX remaining at any time point was calculated as 100% × the
ratio of remaining drug amount to the total drug spiked into this volume of plasma. The
concentration of DX in the same sample was determined by LC/MS/MS. The % 2-Br-C16-
DX hydrolyzed to DX at any time point was calculated as 100% × [(DX amount detected ×
1124 / 807)/ the total drug spiked into this volume of plasma].
Preparation and characterization of 2-Br-C16-DX NPs
NPs containing 2-Br-C16-DX were prepared using a warm oil-in-water (o/w)
microemulsion precursor method previously developed and later optimized in our
laboratory.[4, 21] For in-vivo studies, NPs were concentrated and PEGylated. The
formulation was concentrated 4–13-fold by adding 4–13-fold less 10% lactose continuous
phase while keeping the other components of the formulation unchanged. The NPs were
PEGylated by adding 8% Brij 700 during the preparation wherein 8% was the w/w ratio of
Brij 700 to Miglyol 808.
Particle size and the zeta potential of NPs were determined as previously described.[4] Drug
entrapment efficiency was determined by size exclusion chromatography (SEC) as
previously described.[4] The 2-Br-C16-DX NP suspension was stored at 4°C. At designated
time points, the particle size was measured after the NP suspension being allowed to
equilibrate to room temperature. The 2-Br-C16-DX concentration was then determined by
HPLC.
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In-vitro drug release in mouse plasma
In-vitro release studies were performed in 100% plasma from BALB/c mice. Briefly, 100 µL
of purified DX conjugate NPs were spiked into 2 mL of mouse plasma. The release mixture
was incubated at 37°C in a water bath shaker. At designated time points from 0 hr to 8 hr,
two aliquots of release mixture were removed. One aliquot (100 µL) was used to determine
the total drug concentration by solid phase extraction (SPE) using Hybrid-SPE precipitate
method. Briefly, one volume of release mixture was mixed with three volumes of 2% formic
acid in ACN. Following vortex and centrifugation, the supernatant was applied to a Hybrid-
SPE cartridge. The eluate was collected for HPLC analysis. Another aliquot (100 µL) was
used to determine the drug remained in the NPs using the method described in drug
entrapment efficiency determination. The Sepharose CL-4B column was able to achieve
baseline separation of the NPs with plasma proteins and free drugs, validated by dynamic
light scattering intensity, BCA assay and HPLC analysis (data not shown). The % DX
released at any time point was calculated as 100% × [(Total drug detected – drug remaining
in the NPs)/Total drug detected].
Evaluation of in-vitro cytotoxicity
The MTT assay was utilized to assess cytotoxicity of free 2-Br-C16-DX and the 2-Br-C16-
DX NPs. Serial dilutions of free drugs or drug containing NPs were added to the DU-145
cells or 4T1 cells and incubated for 48 hr. The cells were then incubated with MTT solution
for 4 hr and the formazan dyes were solubilized by DMSO. The absorbance was measured at
a wavelength of 570 nm, and the concentration of drug that inhibited cell survival by 50%
(IC50) was determined from cell survival plots.
In-vivo pharmacokinetics of 2-Br-C16-DX NPs
Female BALB/c mice were injected s.c. in the right flank 1 × 10−6 4T1 cells suspended in
100 µL of FBS-free RPMI-1640 medium. When the tumor volume reached 400 – 500 mm3,
mice were randomly divided into two groups. The mice (n=3/time point) were injected via
tail vein with Taxotere or 2-Br-C16-DX NPs, all at a DX dose of 10 mg/kg. At designated
time points from 3 min to 96 hr, the mice were given an overdose of ketamine (100 mg/kg)
and domitor (0.5 mg/kg) for deep anesthesia prior to cardiac puncture to collect blood and a
cervical dislocation was then performed to euthanize the mice. After euthanasia, organs
(heart, liver, spleen, lung and kidney) and tumor were collected and flash frozen in liquid
nitrogen. For plasma separation, the blood collected in heparin-coated tubes was centrifuged
at 12,300 rpm for 15 min. The obtained plasma was processed with Hybrid-SPE precipitate
method as described above. For organs and tumor, 300 µL of 2% formic acid in ACN was
added to every 100 mg of tissues. Tissues were homogenized using Omni Bead Ruptor 24
homogenizer with 2.8 mm zirconium oxide beads. Following vortex and centrifugation, the
supernatant was applied to a Hybrid-SPE cartridge. The eluate was collected for analysis.
The concentrations of 2-Br-C16-DX in plasma and tissue extract were determined by HPLC,
and the DX concentrations were quantified by LC/MS. Pharmacokinetic analysis and
modeling was performed by WinNonlin (version 5.2.1; Pharsight Corp, Mountain View,
CA).
In-vivo antitumor efficacy
Female BALB/c mice were injected s.c. in the right flank 1 × 10−6 4T1 cells suspended in
100 µL of FBS-free RPMI-1640 medium. When the tumor volume reached 70 – 100 mm3,
mice were randomly divided into multiple groups. In the first efficacy study, the mice (n =
8) were injected via tail vein with test samples twice per week (10 mg conjugate/kg from 2-
Br-C16-DX NPs, 10 mg DX/kg from Taxotere, and 10 mg conjugate/kg from 2-Br-C16-DX
in the Taxotere vehicle). In the second efficacy study, the mice (n = 9) were injected via tail
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vein with test samples Q7d × 2 (70 mg conjugate/kg from 2-Br-C16-DX NPs, 70 mg/kg
equivalent blank NPs, 20 mg DX/kg from Taxotere, and 10 mg conjugate/kg from 2-Br-
C16-DX in the Taxotere vehicle). Tumor volume was measured by caliper three times per
week. Tumor volume was calculated as length × (width)2/2. The body weight and body
conditions were monitored as well. Tumor growth and mouse mortality were recorded until
day 23. Percentage survival of each group was calculated and plotted for the second efficacy
study.
Statistical analysis
Statistical comparisons were performed using analysis of variances (ANOVA) (©1992–2007
GraphPad Prism Software, Inc.). Results were considered significant at 95% confidence
interval (P < 0.05).
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Synthesis of 2’-(2-bromohexadecanoyl)-docetaxel conjugate
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The digestion of 2-Br-C16-DX in fresh 100% mouse plasma at 37°C. Data are shown as
mean ± SD (n = 3).
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Release of 2-Br-C16-DX from NPs in 100% mouse plasma at 37°C.
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In-vitro cytotoxicity of free 2-Br-C16-DX and 2-Br-C16-DX NPs in (A) human prostate
cancer cell DU-145 cells and (B) murine breast cancer cell 4T1 cells. Blank NPs were dosed
at drug equivalent dose. Drug equivalent dose of NPs are calculated from the NP
compositions.
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Plasma concentration-time curves for (A) DX and 2-Br-C16-DX after administration of
Taxotere and 2-Br-C16-DX NPs (10 mg DX/kg from each), and (B) DX as an active
metabolite from 2-Br-C16-DX NPs using Taxotere as a reference. Data are shown as mean ±
SD (n = 3).
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Biodistribution of (A) 2-Br-C16-DX and (B) DX in heart, liver, spleen, lung, kidney and
tumor after i.v. administration of 2-Br-C16-DX NP and Taxotere (10 mg DX/kg from each).
Data are shown as mean ± SD (n = 3).
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Tumor accumulation of (A) 2-Br-C16-DX from NPs and DX from Taxotere, and (B) DX as
an active metabolite from 2-Br-C16-DX NPs after i.v. administration of 2-Br-C16-DX NP
and Taxotere (10 mg DX/kg) using Taxotere as a reference. Data are shown as mean ± SD
(n = 3).
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The first antitumor efficacy study. 4T1 bearing female BALB/c mice bearing 70 – 100 mm3
tumor were treated i.v. with 10 mg conjugate/kg from 2-Br-C16-DX NPs, 10 mg DX/kg
from Taxotere, or 10 mg conjugate/kg from 2-Br-C16-DX in the Taxotere vehicle on day 0,
3, 7, 10, and 14. Data are shown as mean ± SD (n = 8). * p < 0.05.
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The second antitumor efficacy study. 4T1 bearing female BALB/c mice bearing 70 – 100
mm3 tumor were treated i.v. with 70 mg conjugate/kg from 2-Br-C16-DX NPs, 70 mg/kg
equivalent blank NPs, 20 mg DX/kg from Taxotere, or 10 mg conjugate/kg from 2-Br-C16-
DX in the Taxotere vehicle on day 0 and 7. Data are shown as mean ± SD (n = 9). * p <
0.05.
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Kaplan-Meier survival curves of 4T1 bearing female BALB/c mice treated with 70 mg
conjugate/kg from 2-Br-C16-DX NPs, 70 mg/kg equivalent blank NPs, 20 mg DX/kg from
Taxotere, or 10 mg conjugate/kg from 2-Br-C16-DX in Taxotere vehicle (n=9) on day 0 and
7.
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Table 1
Pharmacokinetic parameters of 2-Br-C16-DX and DX in mice after i.v. bolus administration of 2-Br-C16-DX





t1/2 (hr) 4.04 35.3 5.62
AUC0–96 (h*mg/L) 2.36 230 10.1
AUC0–∞ (h*mg/L) 2.47 265 10.6
Vd (L/kg) 4.48 0.55 --
Kel (1/hr) 0.17 0.02 0.12
CL (L/hr/kg) 4.05 0.04 --
Cmax (mg/L) 10.5 192 2.59
MRT (hr) 1.10 15.2 7.06
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Table 2






AUC0–96 (µg/g*h) 7.10 70.6 10.4
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